InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$72.57

2026-10-16

Market Cap

$11.4B

Volume

2.6M

52-Wk High

$72.69

52-Wk Low

$43.20

Trailing PE

62.0

P/S

9.37

Gross Margin

65.8%

Net Margin

15.0%

ROE

9%

ROIC

8%

Piotroski

8/9

Altman Z

15.9

1-Yr Return

+18.0%

5-Yr Return

+55.0%

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

SectorHealthcareIndustryBiotechnologyExchangeNASDAQMarket Cap$11.4BEmployees3,000 (SEC-filed)CEOKim KeldermanIPO1989-02-09CountryUS

614 McKinley Place N.E., Minneapolis, MN 55413 · Tel 612 379 8854 · bio-techne.com

INSIDERSTREET SCORE70 / 100Street mean $73.00 (1 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$0M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · TECH +18.0% · S&P 500 +15.9% · spread +2.1pp

7 Years vs S&P 500 · TECH +55.0% · S&P 500 +189.9% · spread -134.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE70of 100

Score Breakdown

Profitability	61/100
Growth	56/100
Momentum	85/100
Quality	83/100
Earnings Quality	73/100
Balance Sheet	83/100
Value	43/100
Risk (safety)	100/100
Overall	70.0/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
BMRN	47
MDGL	40
BBIO	30
IBRX	22
JAZZ	72
NBIX	82
TECH	70

IS Score Trend — quarterly

16 quarters, 23 Q1 to 26 Q4. Peak 75 in 23 Q1, latest 70 — -5 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY70 / 100IS Score 70.0 / 100 · -4.9 from peak of 75

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 82 / 100 · Power +64 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 70 and price structure at 82 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 70.0	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 55 → 55 → 61 → 70	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 596 → now 596	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)0none disclosed

ETF Funds (30d)541 up / 470 downnet +71 funds

Institutions Added (13F)15managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 596 · latest 596 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	596	175.7M	$12.3B	112.6%	ex-outlier 103.7%
2026 Q1	581	175.0M	$8.9B	112.2%	ex-outlier 104.4%
2025 Q4	581	168.9M	$9.5B	108.3%
2025 Q3	571	155.7M	$8.4B	99.8%
2025 Q2	553	155.5M	$7.5B	99.7%
2025 Q1	578	159.1M	$8.6B	102.0%
2024 Q4	574	152.8M	$10.2B	97.9%
2024 Q3	559	151.1M	$11.2B	96.8%
2024 Q2	571	152.2M	$10.2B	97.6%
2024 Q1	553	153.8M	$10.4B	98.6%
2023 Q4	526	150.8M	$11.4B	96.7%
2023 Q3	525	147.5M	$9.8B	94.6%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2026-06 reads 112.64%. Institutions cannot hold more of a company than exists. The reported 175.7M shares exceed the 156.0M outstanding, and a single filer accounts for the excess: BlackRock, Inc. reports 14,025,816 shares against 12,264,513 the prior quarter, a 1x jump, which alone would be 9.0% of the company. Excluding that filing, ownership is 103.7%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Why 2026-03 reads 112.23%. Institutions cannot hold more of a company than exists. The reported 175.0M shares exceed the 156.0M outstanding, and a single filer accounts for the excess: BlackRock, Inc. reports 12,264,513 shares against 12,129,125 the prior quarter, a 1x jump, which alone would be 7.9% of the company. Excluding that filing, ownership is 104.4%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Higgins John L	director	2026-09-28	EXERCISE	15,940	—	82,816
Higgins John L	director	2026-09-28	TAX W/H	5,562	$0.40M	77,254
Higgins John L	director	2026-09-28	EXERCISE	15,940	$0.40M	0
Baumgartner Robert V	director	2026-09-22	EXERCISE	15,940	—	62,443
Baumgartner Robert V	director	2026-09-22	TAX W/H	5,559	$0.40M	56,884
Baumgartner Robert V	director	2026-09-22	EXERCISE	15,940	$0.40M	0
Herr Amy E.	director	2026-08-17	A-Award	1,381	—	1,381
Bohnen Shane	SVP - General Counsel	2026-08-17	A-Award	11,344	—	11,344

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	1	6,636	$0.3M	Counted
M — Exercises (paired A/D)	35	394,648	$15.6M	None — mechanics
F — Tax withholding	20	290,561	$18.4M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$0.3M1 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-05-08	Joshua Molho	6,636	$0.3M
2026-02-17	Joshua Molho	1,976	$0.1M
2025-08-25	Robert V. Baumgartner4731 Bonita Bay Boulevard	17,040	$1.0M
2025-08-25	Roeland Nusse	17,040	$1.0M
Trailing 12 mo	4 filings	42,692	$2M

Filed	Form	Reporting person	% of class	Shares
2026-08-06	SCHEDULE 13G/A	Abigail P. Johnson	8.10%	12.8M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.38%	11.6M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-11-14	SCHEDULE 13G/A	T. Rowe Price Associates, Inc.	2.20%	3.4M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
April Delaney	House	SELL	$1,001 - $15,000	2026-04-08	2026-05-07
April McClain Delaney	House	SELL	$1,001 - $15,000	2026-04-08	2026-05-07
April McClain Delaney	House	SELL	$1,001 - $15,000	2026-04-07	2026-05-07
Thom Tillis	Senate	SELL	$1,001 - $15,000	2015-02-13	2015-02-26

House 12-Mo20 trades8 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)581

13F Shares175M112.2% of shares out

New / Closed72 / 59positions, QoQ

Increased / Reduced199 / 223positions, QoQ

Put/Call (13F)1.00option positions

Free Float99.4%156M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Border To Coast Pensions Partnersh	561,827	$41M
Czech National Bank	44,986	$3M
Midwest Financial Partners Investm	27,291	$2M
Gateway Investment Advisers Llc	25,064	$2M
Wealth Enhancement Advisory Servic	15,436	$1M
State Of Alaska, Department Of Rev	14,831	$1M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$361M
VTSAX	0.0%	$361M
VSMPX	0.0%	$361M
VTI	0.0%	$361M
VOO	0.0%	$298M
VFFSX	0.0%	$298M

13F Filers Holding TECH — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session27.3%2026-10-15

20-Day Avg33.2%50-day 32.0%

TrendRising20d vs 50d

By Market CenterQ: 27% · N: 13% · B: 84%latest session

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Weekly Notional ($B)

Where TECH Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	3.1M	50 sh
Ubsa Ubs Ats	3.0M	70 sh
Sgmt Sigma X2	1.8M	50 sh
Ebxl Level Ats	1.6M	37 sh
Mstx Ms Trajectory Cross (Ats-1)	1.5M	52 sh
Bids Bids Ats	1.2M	494 sh

Where a dollar of Bio-Techne Corporation revenue goes. All values FY2026 filings, live.

Region	Revenue	Share
U S	$635M	52%
Europe	$294M	24%
C N	$104M	9%
APAC, excluding Greater China	$86M	7%
UNITED KINGDOM	$56M	5%
Rest Of World	$39M	3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECH (live moat model)Peer median: BMRN · MDGL · BBIO · IBRX · JAZZ

Component scores from the live moat model. Peer median illustrative.

Moat score 41/100 — Weak; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Kim Kelderman	Chief Executive Officer, President & Director
James T. Hippel	Executive Vice President of Finance & Chief Financial Officer
William A. Geist	President of Protein Sciences Segment
Shane Bohnen	Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer

Revenue ($M)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)3 of 6recent quarters

Avg Surprise+3.2%

Next Report2026-11-04

Income Quality1.61OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY22	FY23	FY24	FY25	FY26
Revenue	+18.7%	+2.8%	+2.0%	+5.2%	-0.4%
Gross profit	+19.5%	+1.8%	-0.0%	+2.7%	+1.1%
Operating income	+25.0%	+0.8%	-30.9%	-50.5%	+146.3%
Net income	+93.8%	+4.9%	-41.1%	-56.3%	+147.8%

$M · FY ends	FY22	FY23	FY24	FY25	FY26
Revenue	1,106	1,137	1,159	1,220	1,215
Cost of revenue	349	367	389	429	416
Gross profit	756	770	770	790	799
R&D expense	87	92	97	99	95
SG&A expense	339	352	393	415	452
Operating income	297	299	207	102	252
EBITDA	414	457	313	217	343
D&A	101	107	112	110	97
Pretax income	301	339	186	98	241
Income tax	38	53	18	25	59
Net income	272	285	168	73	182
Diluted EPS ($)	1.66	1.76	1.05	0.46	1.16
Diluted shares (M)	164	162	161	160	157

Operating CF$292M

CapEx$29M

Free cash flow$263M

SBC$41M

Buybacks$42M

Net cash change$103M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$M	FY23	FY24	FY25	FY26
Cash & equivalents	180.6	151.8	162.2	264.7
ST investments	23.7	1.1	0.0	0.0
Receivables (net)	218.5	241.4	206.9	220.5
Total current assets	621.5	617.4	608.3	744.4
PP&E (net)	324.5	342.4	319.1	299.2
Goodwill + intangibles	1,407.4	1,479.7	1,346.5	1,278.8
Total assets	2,638.7	2,703.9	2,557.9	2,679.0
Accounts payable	25.7	38.0	25.3	26.7
Short-term debt	0.0	0.0	0.0	14.9
Deferred revenue	23.1	27.9	32.6	36.1
Total current liabilities	128.5	159.4	175.8	163.7
Long-term debt	350.0	319.0	346.0	200.0
Total liabilities	672.2	635.0	639.1	570.8
Shareholders' equity	1,966.5	2,068.8	1,918.8	2,108.2

Cash Flow Statement — Full

$M	FY23	FY24	FY25	FY26
Net income	285.4	168.1	73.4	181.9
D&A	107.2	111.7	109.9	97.4
Stock-based compensation	39.2	38.0	40.8	41.4
Working capital change	(90.6)	(10.1)	11.5	(41.3)
Operating cash flow	254.4	299.0	287.6	292.1
Capital expenditures	(38.2)	(62.9)	(31.0)	(28.8)
Investing cash flow	(265.6)	(203.0)	(35.2)	(18.2)
Buybacks	(19.6)	(80.0)	(275.7)	(41.7)
Dividends paid	(50.3)	(50.4)	(50.4)	(49.9)
Debt issuance / (repay)	94.0	(31.0)	27.0	(146.0)
Financing cash flow	22.6	(122.4)	(253.9)	(169.1)
Free cash flow	216.1	236.1	256.6	263.2

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
PROFITABILITY
ROE	16.7%	15.6%	8.3%	3.7%	9.0%	9%
ROA	11.9%	11.6%	6.3%	2.8%	6.9%	7.0%
ROIC	14.5%	11.4%	8.0%	3.5%	8.9%	7.8%
Gross margin	68.4%	67.7%	66.4%	64.8%	65.8%	65.8%
Operating margin	26.8%	26.3%	17.8%	8.4%	20.7%	20.7%
Net margin	24.6%	25.1%	14.5%	6.0%	15.0%	15.0%
EBITDA margin	37.4%	40.2%	27.0%	17.8%	28.3%	28.3%
FCF margin	25.4%	19.0%	20.4%	21.0%	21.7%	—
VALUATION
P/E	51.26	45.76	67.94	108.88	61.00	62.0
P/B	8.19	6.64	5.52	4.17	5.26	5.4
P/S	12.61	11.48	9.85	6.55	9.13	9.37
P/FCF	49.74	60.39	48.37	31.15	42.14	43.2
EV/EBITDA	33.89	28.64	37.32	38.15	32.37	33.2
EV/Revenue	12.68	11.70	10.08	6.78	9.15	9.4
Earnings yield	2.0%	2.2%	1.5%	0.9%	1.6%	1.61%
FCF yield	2.0%	1.7%	2.1%	3.2%	2.4%	2.31%

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
LEVERAGE & SOLVENCY
Current ratio	3.44	4.84	3.87	3.46	4.55	4.55
Quick ratio	2.64	3.50	2.75	2.38	3.35	3.35
Debt / equity	0.19	0.23	0.20	0.23	0.14	0.14
Debt / assets	14.2%	17.2%	15.5%	17.4%	10.8%	11.2%
Net debt / EBITDA	0.19	0.54	0.85	1.30	0.07	0.07
Interest coverage	27.65	31.87	12.80	12.57	45.53	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
EFFICIENCY
Asset turnover	0.49	0.46	0.43	0.46	0.46	0.47
Receivables turnover	6.50	5.50	5.04	5.44	5.74	5.6
DSO (days)	56	66	72	67	64	65
DPO (days)	33	30	30	27	23	92
Cash conversion cycle	158	192	207	197	210	145
GROWTH (YoY)
Revenue growth	18.7%	2.8%	2.0%	5.2%	-0.4%	—
Net income growth	93.8%	4.9%	-41.1%	-56.3%	147.8%	—
EPS growth	94.0%	5.9%	-40.6%	-55.0%	145.8%	—
FCF growth	-8.9%	-22.9%	9.2%	8.7%	2.6%	—
PER SHARE ($)
EPS (diluted, TTM)	1.66	1.76	1.05	0.47	1.16	1.17
Book value / share	10.40	12.14	12.88	12.32	13.43	13.52
Revenue / share	6.76	7.02	7.21	7.83	7.74	7.79
FCF / share	1.71	1.33	1.47	1.65	1.68	1.69
Cash / share	1.51	1.26	0.95	1.04	1.69	1.70
SHAREHOLDER RETURN & SCORES
Buyback yield	1.2%	0.2%	0.7%	3.5%	0.4%	0.38%
Altman Z-Score	15.93	13.45	12.35	8.90	13.28	15.9
Piotroski F-Score	9	4	6	5	7	8/9
Beneish M-Score	-2.35	-2.23	-2.59	-2.88	-3.30	-3.30

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	15.9	Safe (>2.99)	Safe
Income quality	1.61	Cash-backed	OCF ÷ net income
Beneish M-Score	-3.30	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.76
Interest burden	0.98
Operating margin	20.3%
Asset turnover	0.46×
Financial leverage	1.30×
= ROE	9%

Growth Quality (live)	Value
Revenue stability	0.88
Earnings stability	0.11
Earnings persistence	0.50
Revenue CAGR 3y	2.2%
EPS CAGR 3y	-13.0%
FCF CAGR 3y	6.8%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.38%

Dividend Yield0.44%

Total Shareholder Return0.31%cash yield

SBC / Revenue3.4%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
BMRN	$10.6B	143.9	1%	4.5%	+11.2%	4/9	+3.3%
MDGL	$10.4B	-34.9	-53%	-15.9%	+149.0%	2/9	+1.7%
BBIO	$13.0B	-18.5	32%	-62.5%	+202.4%	4/9	+20.6%
IBRX	$9.7B	-9.4	123%	—	+192.9%	4/9	+262.8%
JAZZ	$13.6B	13.8	22%	16.0%	+12.6%	8/9	—
NBIX	$13.8B	19.2	22%	15.1%	+34.4%	6/9	—
KRYS	$9.4B	38.3	20%	45.9%	+22.6%	7/9	—
HALO	$13.8B	34.6	174%	47.8%	+41.2%	5/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

26 Analysts

Str Sell (0)Sell (0)Hold (14)Buy (12)Str Buy (0)

Mean Target (qtr)$73.001 targets

Target vs. Price+0.6%last-quarter mean

Next Report2026-11-04street $0.44

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$1.21B	$1.22B / $1.20B	$1.92	$1.95 / $1.87	8
FY2027	$1.27B	$1.29B / $1.25B	$2.03	$2.10 / $1.96	7
FY2028	$1.40B	$1.43B / $1.39B	$2.38	$2.46 / $2.29	5

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Quarter	$73.00	+0.6%	1
Last Year	$66.18	-8.8%	17
All Time	$77.16	+6.3%	29

Rolling mean of published targets vs. last close $72.57. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

3/5

ROE

3/5

ROA

5/5

Debt/Eq

3/5

P/E

1/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECH +18.0% vs S&P 500 +15.9% — spread +2.1pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$72.50	+0.07	+0.10%	Above
SMA 50	$72.37	+0.20	+0.28%	Above
SMA 200	$62.72	+9.85	+15.70%	Above
EMA 9	$72.51	+0.06	+0.08%	Above
EMA 21	$72.46	+0.11	+0.15%	Above
EMA 50	$71.56	+1.01	+1.41%	Above
EMA 200	$64.97	+7.60	+11.70%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

TECHNICAL VERDICTBULLISHPower Score +6419 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%90

Volume 20%69

Volatility 10%83

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago91%+9 pts since

ReadStabilizingweek-over-week trajectory

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Price vs SMA 20$72.50

Price vs SMA 50$72.37

Price vs SMA 200$62.72

EMA 9/21 Cross72.5/72.5

SMA 50/200Golden

ADX DirectionADX 37

Supertrend$72

Parabolic SAR$72

SMA Slope0.010

RSI58.4

Stochastic K/D66/59

StochRSI K/D29/18

Williams %R-14

CCI49

TSI vs Signal13.8

CMO16.7

ROC0.23%

OBV SignalAccum

Chaikin MF-0.270

MFI39

Force Index0M

Elder Ray Bull0.13

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 59

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$72.54 / $72.59 / $72.65	S1 / S2	$72.48 / $72.43
Bollinger (20,2)	$72.37 – $72.63	Squeeze	ON
52-wk range	$43.12 – $72.69	Off 52-wk high	-0.2%
ATR (14)	$0.16 (0.2%)	Historical vol	1.9%

-0.5%Jan45%

-0.4%Feb60%

-0.2%Mar48%

+1.2%Apr60%

+2.6%May60%

+1.3%Jun60%

+2.2%Jul70%

-1.4%Aug35%

-0.5%Sep55%

-0.7%Oct50%

+2.2%Nov70%

+1.5%Dec60%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	TECH	S&P 500
Weekly volatility (σ, 1y)	6.36%	1.83%
Best / worst week (1y)	+25.6% / -12.3%	—
Max drawdown (5y, monthly)	-62.6%	—
1-week VaR (95%)	-9.3%	—
Beta (5y)	1.27	1.00

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECH EQUITY WEATHER (LIVE)CLOUDY · +13

Trend+42

Momentum+17

Volume+19

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 3,357 stories, weekly buckets, −1 to +1.

Overall+13.2+50.7 vs industry

Trend+41.9+81.3 vs industry

Momentum+17.0+65.5 vs industry

Volume+19.3+58.1 vs industry

Reading	TECH	Biotechnology n=1,668	Healthcare n=5,272	All US symbols n=70,435
Overall	+13.2	-37.6	-24.0	-20.5
Trend	+41.9	-39.5	-25.6	-21.3
Momentum	+17.0	-48.5	-28.5	-15.8
Volume	+19.3	-38.8	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Kim Kelderman President and CEO	$8.2M	64% equity+incentive
James Hippel Executive Vice President and CF	$7.0M	77% equity+incentive
William Geist President, Protein Sciences	$3.1M	62% equity+incentive
Matthew McManus President, Diagnostics and S	$2.8M	58% equity+incentive
Shane Bohnen Senior Vice President and Gener	$2.0M	58% equity+incentive

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Pillar (live disclosure scores)	Score
Environmental	57
Social	58
Governance	54
Composite ESG	56

Composite ESG Trend

Filed	8-K contents	Items
2026-09-23	Shareholder Vote; Regulation FD; Exhibits	5.07,7.01,9.01
2026-09-14	Other Events	8.01
2026-08-12	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-06-26	Material Agreement; Officer/Director Change; Exhibits	1.01,5.02,9.01
2026-06-25	Regulation FD; Exhibits	7.01,9.01
2026-05-06	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-02-11	Departure/Election of Directors; Appointment of Officers; Other Events	5.02,8.01,9.01
2026-02-04	Results of Operations and Financial Condition; Other Events; Financial	2.02,8.01,9.01

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2021 to 2026
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-08-12
Analyst estimates	dim/forward_estimates	3 rows · 2026-06-30 to 2028-06-30
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	50 rows · 2009 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-17 to 2026-09-28
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-11-14 to 2026-08-06
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Bio-Techne Corporation (TECH)

Institutions holding — 12 quarters

Bio-Techne Corporation (TECH)

Monthly Net Insider Flow (000 shares)

Signal Summary

Bio-Techne Corporation (TECH)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding TECH — quarterly

Institutional Put/Call — quarterly

Bio-Techne Corporation (TECH)

Where TECH Trades in the Dark

Bio-Techne Corporation (TECH)

3.8 · Employees (SEC filings)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Balance Sheet — Full

Cash Flow Statement — Full

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Street Price Target — Trajectory

Third-Party Composite Rating

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Family Scores (site weights)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH)